



Iceland

Annual Report 2017

The Nordic Cancer Union



Contents

| | |
|--|---|
| 3 | NCU in short |
| 7 | NCU Scientific Committee recommendations 2017 |
| 14 | Awarded research grants 2017 |
| 15 | NCU Strategic Funds |
| 18 | NCU financial statements 2017 |
| 19 | NCU member information |
| Appendix 1 The NCU financial statements 2017 | |



Nordic Cancer Union
www.ncu.nu

NCU Secretariat

c/o **The Icelandic Cancer Society**, Skógarhlíð 8, IS–105 Reykjavík, Iceland, att. Ragnheiður Haraldsdóttir, NCU chairman, Phone: +354 5401900 and +354 8950218, e-mail: rag-nhara@krabb.is and Ingimar Einarsson, NCU secretary, Phone: +354 8916356, e-mail: ingimare@simnet.is

NCU Research Administration

c/o **The Norwegian Cancer Society** (Kreftforeningen), Postboks 4 Sentrum 0101 Oslo, Norway, att. Janina Lassila, special executive officer, Phone: +47 900 32 397, e-mail: ncu@kreftforeningen.no and Janina.Lassila@kreftforeningen.no

NCU *in short*



*Ragnheiður Haraldsdóttir,
NCU chairman*

The Nordic Cancer Union (NCU) was founded in 1949 to enhance collaboration between the cancer societies in the Nordic countries. Its main aim is co-operation on relevant strategic issues, exchange of experiences, and to be a forum for inspiration for the Danish Cancer Society, the Faroe Cancer Society, the Cancer Society of Finland, the Icelandic Cancer Society, the Norwegian Cancer Society and the Swedish Cancer Society.

The NCU is directed by a board comprising representatives of each of the member organizations. The chairmanship of the board is responsible for the NCU's function during a three year mandate period. The strategies and priorities for the NCU are stipulated by the board and should be valid during the three year alternating chairmanship of the member organizations. The Icelandic Cancer Society chairs the NCU Secretariat from 2015 to 2017. In November 2017 the NCU Board decided, that the Danish Cancer Society would be responsible for the NCU secretariats during 2018 – 2020.

In 2017 the Icelandic Cancer Society, through chairmanship of the NCU, coordinated the collaborative activities of the NCU and organized four NCU board meetings. These meetings were held in Stockholm in February, in Copenhagen in May, in Stavanger in September, and in Reykjavik in November. The meeting in Stavanger was in combination with NCU and ANCR (Association of Nordic Cancer Registries) joint symposium.

At the core of the work of the NCU is the sharing of experiences and ideas. Reports from each country at each board meeting are thus probably the most important aspect of the work, and the NCU forum in 2017 served the member organizations well and was inspirational,- as always.

Strategic Plan 2018 – 2020

In August 2017 it was decided that the existing Strategic Plan 2015-2018, including the 5 earlier overall defined themes, will continue in the period 2018-2020. The decision was taken on the basis, that NCU had a thorough review of the NCU statutes in 2015-2016, and that NCU's statutes

are therefore up-to-date and form a framework with a through line that allows NCU to raise issues and act if / when there is desire and will.

NordForsk

In February, representatives from NordForsk were invited to the board meeting of the NCU. NordForsk, which is an organization under the Nordic Council of Ministers, was established in 2005 for the purpose of strengthening Nordic research. The NCU board and the representatives from NordForsk concluded that there are topics of common interest to build on.

Cancer prevention and WHO

A resolution on Cancer prevention and control in the context of an integrated approach was in the beginning of 2017 being prepared to be approved at the World Health Assembly in May 2017. The members of the board of NCU discussed the content of the draft resolution and made their comments to the health authorities in the Nordic countries. The resolution proposed was adopted by the WHO Assembly on the 29 May with only minor changes.

Collaboration with the Nordic Council of Ministers

In 2012, the NCU initiated collaboration with the Nordic Council of Ministers advocating for a stronger emphasis on health and cancer in the work of the Council. On the 30 October 2013 the Nordic Council adopted a resolution concerning focus on long-term perspectives on cancer in the Nordic countries and cooperation between NCU, the Nordic Council and the Nordic Council of Ministers. At the meeting of the NCU board in May 2017 a status report was presented based on information from the Nordic Council of Ministers. The main conclusion of the Board was, that the members of the NCU would concentrate on working with their national governments for the time being.

NORDSCREEN

In February and May 2017, the project NORDSCREEN was presented and discussed at the meetings of the board of the NCU. The aim of the project is to develop a publicly available web-based interactive tool/application to access, compile and visualize standardized performance and outcome indicators of cancer screening based on up-to-date Nordic cancer screening register data. The Board found the project interesting, but was not suitable for financial support by the NCU at the time being.

Cancer medicines

Access to new cancer medicines was on the agenda at the Board meeting in Copenhagen. The new cancer medicines are very effective, but the extensive cost prohibits their common use in many countries. In the Nordic countries, there are different regulations concerning the uptake of expensive new medicines and the discussions of a common Nordic market have so far shown limited results.

Antibiotics resistance

At the Board meeting in Stavanger attention was drawn to the fact that antibiotics are no longer as effective against resistant bacteria as previously, and that it could have serious consequences for cancer treatment in the future. Thus, an increased prevalence of antibiotic resistance combined with a lack of development of new antibiotics may become one of the worlds greatest threats to public health. The Norwegian Cancer Society had launched a global campaign to raise awareness about antimicrobial resistance (AMR) among cancer organizations. Still, some of the Nordic cancer leagues were of the opinion that these concerns were currently well represented and sufficiently taken care of by the World Health Organization. Opinions differed concerning what role NCU could play in this context and therefore an agreement on common statement was not reached.

Tobacco control

Another issue raised in Stavanger concerned joint meetings on tobacco control. The background was that in March 2014 several Nordic representatives of tobacco control met at EcToH Istanbul (European Conference on Tobacco and Health) and decided to establish a Nordic Tobacco Control Network. This network organized its first meeting in Helsinki in 2015 and all NCU countries were represented. It was consequently recommended, that NCU countries should have regular meetings with the Nordic NGOs and the Nordic Authorities on tobacco control, starting on the 21 of September 2017. After a discussion, it was concluded that participation in meetings with these networks would be for the individual Nordic cancer leagues to decide.

Effect of NCU funding research

The effect of NCU funding of research, that NCU supports has been discussed at all Board meetings in 2017. A working group proposed two ideas, that could shed light over the effect. Firstly, making a short survey that could be send to researcher, who received funds from NCU in a period of 3-5 years and asking questions regarding results from their funding, such as type of publication, presentations, and effects regarding further collaboration with other Nordic researcher, and so on. Secondly, making a small bibliometric analysis of NCU funded research. These two approaches were both implemented. The Board of the NCU was pleased to find that the funding it provides has served as "seed money" for many studies and provided the necessary funding for researchers to succeed in their work. The November meeting was partly dedicated to research activities and as usual the chairman of the research committee presented its recommendations and the Board made its decisions.

CRUK and NordForsk

The NCU Board met with both representatives of the Cancer research UK (CRUK) and NordForsk. They expressed an interest in collaboration between the NCU and the these organizations. Kreftforeningen gathered information on the extent to which the individual cancer leagues are working with Nordic or international organizations, to provide a background for discussions and collaboration.

Cost of Cancer in the Nordic countries

The Finnish Cancer League has recently completed a study of the cost of cancer in Finland. The results were presented to the NCU Board in November and a discussion ensued about whether the study could be replicated on a larger scale in all of the Nordic countries. Such a research or a project to prepare for it might possibly be supported by the NCU depending on fulfilling criterias for support.

NCU finances, including research grants

Every year the Nordic Cancer Union grants €750.000 to cancer research. In 2017, the NCU awarded 19 grants totalling €750.000 to cancer research. Grants ranged from €30.000 to €50.000. The total income of the NCU in 2017 was €922.487. Membership fees accounted for €918.810 and the refund from the Nordic summer school accounted for €3.677.

The purpose of the NCU research grants is to support and stimulate collaborative Nordic research that will benefit cancer patients in the Nordic countries. By funding high quality research, the NCU aims to achieve improved knowledge and understanding of cancer diseases, their effective prevention, treatment and/or rehabilitation.

Representatives in the NCU meetings 2017:

Denmark

Leif Vestergaard Pedersen, Managing director of Danish Cancer Society, Elizabeth Hjorth, Legal advisor and Hans Henrik Storm, Chief medical advisor.

Finland

Sakari Karjalainen, Secretary General, Carita Åkerblom, Secretary of Organizational Affairs; Helena Hilkko, Communication- and Fundraising director

Faroe Islands

Durita Tausen, Chairman of the Faroese Cancer Society;

Norway

Anne Lise Ryel, General Secretary, Ole Alexander Opdalshei, Assisting General Secretary and Kirsten Haugland, Head of Research and Prevention;

Sweden

Ulrika Årehed Kågström, General Secretary and Suzanna Wörn, Responsible for Strategic Coordination;

Iceland

Ragnheiður Haraldsdóttir, NCU Chairman, Valgerður Sigurðardóttir, Guðfinna Halla Þorvaldsdóttir and Ingimar Einarsson, NCU Coordinator.

NCU Scientific Committee recommendations 2017

The scientific committee comprises one member with scientific competence from each member country appointed by the NCU Board after recommendations from the national cancer societies.

Members of the scientific committee in 2015-2018 are:

Iceland: Thorunn Rafnar, chairman of the committee, biologist and PhD, works at Cancer Decode Genetics

Denmark: Elsebeth Lynge, professor and mag.scient.soc

The Faroe Islands: Johan Poulsen, physician and urologist

Finland: Klaus Peter Elenius, PhD and professor of medical biochemistry

Norway: Kristina Kjørheim, Chief and Deputy Head of Department for Research in Cancer Registry

Sweden: Klas Kärre, PhD and professor in molecular immunology.

The tasks of the committee are to assess scientific grant applications, secure high scientific quality and formulate recommendations regarding the applications to the Secretaries-General for their decisions on grants, to give consultation concerning strategic projects regarding research to the Secretaries-General for their decisions on grants, and to evaluate funded research and follow-up on the application of the results in the Nordic countries. Each year 750.000 euros are granted for cancer research. The secretariat of the committee is permanently located at the Norwegian Cancer Society.

The NCU has been awarding research grants since 1989. Applications are handled in two phases: beginning with the national expert groups and then by the Nordic Research Committee which comprises one representative from each NCU member country.

NCU grant applications 2017

The Nordic Cancer Union received 42 grant applications in 2017. The annual NCU Scientific Committee meeting was conducted in Reykjavik on November 19, 2017. The committee recommended that 19 projects were granted funding by the NCU Board. A list of the projects for which funding was recommended is presented below. The committee's assessment is based on scientific quality, quality of researchers, level of Nordic synergy, and relevance to NCU's strategy.

The recommendations from the NCU Scientific Committee was approved by the NCU Board 19. November 2017.

Table 1 provides an overview of the number of applications received and the level of funding granted from 2014 to 2017.

Table 1: Number of applications and level of funding granted

| | 2017 | 2016 | 2015 | 2014 |
|---|-----------|-----------|-----------|------------|
| Number of applications received | 42 | 34 | 41 | 35 |
| Number and ratio (%) of applications funded | 19 (45 %) | 16 (47 %) | 16 (39%) | 15 (42,9%) |
| Total amount of funding applied for (€) | 4 042 386 | 3 221 733 | 3 203 311 | 3 727 851 |
| Total amount of funding applied for – successful applications (€) | 1 842 466 | 1 536 475 | 1 217 679 | 1 292 080 |
| Total funding granted (€) | 750 000 | 750 000 | 750 000 | 750 000 |
| Ratio of funding received to amount applied for – successful applications (%) | 40 % | 48 % | 62 % | 58 % |

Conflict of interest in the evaluation process

The chairman of the SC assigned 6-8 in-depth evaluation tasks to each of the committee members. Some of the evaluation tasks were reassigned due to partiality; two members declared partiality for four evaluation tasks; one member declared partiality for three evaluation tasks and one member declared partiality for one evaluation task. “Conflict of interests” were registered instead of evaluation scores.

During the evaluation meeting, committee members did not participate in evaluation of applications in which they had declared partiality. The committee members left the room if they had declared partiality. This was the case in a total of eleven applications in 2017.

Quality of applications

The number of applications is in the higher range compared to previous years (2017:42, 2016:34, 2015:41, 2014:35, 2013:42, 2012:30, 2011:41). Although some applications still fail to fulfill the formal criteria, in general, the committee found the quality of applications to be good.

NCU received applications for 11 on-going and 31 new projects. SC recommends 10 on-going and 9 new projects for funding in 2017. The SC highlights two projects as good examples of quality applications that have an excellent match to NCU’s strategy; Randomized cancer rehabilitation, risk for late effects for cancer survivors (Christoffer Johanssen) and Register based, fertility after cancer treatment (Kenny Alexandra Rodriguez-Wallberg) - *see table 2 on pages 13-14*.

Location of principal investigator

Figure 1 shows the number of applications from each of the Nordic countries in 2017 (determined by the workplace location of the principal investigator). Figure 2 shows the total number of grant applications received by the NCU from 2014 to 2017. Figure 3 shows each location's share of the recommended applications (determined by the workplace location of the principal investigator).

Figure 1: Number of applications (recommended and not recommended) by location in 2017




Figure 2: Total number of applications by location from 2014 to 2017





Figure 3: Share of recommended applications by location from 2014 to 2017



NORDIC COLLABORATION

Collaboration is at the heart of the Nordic Cancer Union. The numbers in Figure 4 refer to all researchers, principal investigators and co-applicants, listed as participants in the projects for which funding is recommended. The specific Nordic country alliances for each project can be seen in the project overview on *pages 13-14*.

Figure 4: Project participants per location



At least two Nordic countries must be involved in research funded by the NCU. Figure 5 shows the number of countries involved in the projects recommended for funding in 2017 (defined by the work place location of the researchers participating in the project).

Figure 5: Number of Nordic countries involved in projects for which funding is recommended




Table 2: Projects recommended to the NCU Board for funding in 2017 – and approved by the Board.

| Principal investigator | Project title | Project workplace (principal investigator) | Applied amount | Recommended amount | Nordic countries involved |
|-------------------------------|--|---|----------------|--------------------|---------------------------|
| Abildgaard, Niels (Den) | Magnolia Study. Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 3 multi-center Nordic randomised trial. | Odense University Hospital, Department of Haematology. | € 62 000 | € 40 000 | No, Swe, Den |
| Akre, Olof (Swe) | SPCG-15: Surgery versus radiotherapy for locally advanced prostate cancer: a randomized clinical trial | Karolinska Institutet | € 50 000 | € 50 000 | No, Swe, Fin, Den |
| de Boniface, Jana (Swe) | Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial | Dept. of Surgery, Capió St Göran's Hospital, and Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm | € 186 660 | € 30 000 | Swe, Den |
| Engholm, Gerda (Den) | NORDCAN development. Differences in cancer survival in the Nordic countries: the role of stage at presentation, treatment, comorbidity and education | Danish Cancer Society | € 70 000 | € 50 000 | No, Swe, Ice, Fin, Den |
| Grønberg, Bjørn H. (No) | A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer | Norwegian University of Science and Technology and St. Olavs hospital, Trondheim University Hospital | € 79 000 | € 40 000 | No, Swe, Den |
| Gunnarsson, Ulf (Swe) | MSI in sporadic colorectal cancer: register data regarding cancer in other organs, clinical presentation and immune response | Umeå University, Department of Surgical and Perioperative Sciences | € 122 700 | € 40 000 | Swe, Fin |
| Harris, Jennifer (No) | Genetic Epidemiology and Familial Risk of Cross-Cancer Associations: A Nordic Twin Study-II | The Norwegian Institute of Public Health | € 100 000 | € 40 000 | Nor, Swe, Fin, Den |
| Hellström Lindberg, Eva (Swe) | Nordic Collaborative Clinical Database Initiative and Allogeneic Stem Cell Transplantation Project for Myelodysplastic Syndromes | Department of Medicine, Karolinska Institutet, Karolinska University Hospital | € 70 000 | € 40 000 | No, Swe, Fin, Den |
| Jakola, Asgeir S. (Swe, No) | Disulfiram response as add-on to chemotherapy in recurrent glioblastoma | Sahlgrenska University Hospital and St.Olavs Hospital | € 60 000 | € 40 000 | No, Swe, Den |
| Johansen, Christoffer (Den) | Late effects in Nordic cancer patients - LECA | Rigshospitalet and the Danish Cancer Society Research Center | € 90 000 | € 50 000 | No, Swe, Ice, Fin, Den |
| Jonsson, Håkan (Swe) | Estimation of Overdiagnosis in Breast Cancer Screening | Umeå University | € 150 000 | € 40 000 | No, Swe, Fin |

| | | | | | |
|---|---|--|------------|----------|------------------------|
| Kristinsson, Sigurdur Yngvi (Ice) | Comorbidity and multiple myeloma | University of Iceland | € 106 000 | €30 000 | Swe, Ice, Den |
| Lagergren, Jesper (Swe) | Antireflux surgery and cancer risk in the Nordic Antireflux Surgery Cohort (NordASCo) | Karolinska Institutet | €59 106 | €40 000 | No, Swe, Ice, Fin, Den |
| Lindman, Henrik (Swe) | Nordic TRIP – a randomized phase-3 trial of adjuvant and neoadjuvant treatment in early triple negative breast cancer | Onkologiska Kliniken, Akademiska Sjukhuset, Uppsala | €75 000 | €30 000 | No, Swe, Ice, Fin, Den |
| Murtola, Teemu (Fin) | Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial | University of Tampere, Faculty of Medicine and Life Sciences | € 130 000 | €40 000 | Fin, Den |
| Pettersson, Kim (Fin) | Nanoparticle aided glycovariant biomarkers for the early detection of epithelial ovarian cancer | Department of Biochemistry, Division of Biotechnology, University of Turku | € 120 000 | €30 000 | Swe, Fin |
| Pukkala, Eero (Fin) | New wave of joint Nordic studies on work and cancer | Finnish Cancer Registry / University of Tampere | € 150 000 | €40 000 | No, Swe, Fin, Den |
| Rodriguez-Wallberg, Kenny Alexandra (Swe) | An investigation of GnRHa exposure in connection with cancer treatment: Effects on fecundity, cancer recurrence and death | Karolinska Institutet and Karolinska University Hospital | €92 000 | €40 000 | Swe, Fin, Den |
| Tryggvadóttir, Laufey (Ice) | #186457 Prognostic Factors, Treatment and Breast Cancer Survival in Nordic BRCA2 Mutation Carriers | University of Iceland, Icelandic Cancer Society | €70 000 | €40 000 | No, Swe, Ice, Fin, Den |
| Total | | | €1 842 466 | €750 000 | |

Awarded research grants 2017

| Principal investigator | Project Title | Project workplace (principal investigator) | Awarded amount (Euros) |
|-------------------------------|---|---|-------------------------------|
| Abildgaard, Niels | Magnolia Study. Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 3 multicenter Nordic randomised trial. | Odense University Hospital, Department of Haematology. | 40.000 |
| Akre, Olof | SPCG-15: Surgery versus radiotherapy for locally advanced prostate cancer: a randomized clinical trial | Karolinska Institutet | 50.000 |
| de Boniface, Jana | Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial | Dept. of Surgery, Capio St Göran's Hospital, and Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm | 30.000 |
| Engholm, Gerda | NORDCAN development. Differences in cancer survival in the Nordic countries: the role of stage at presentation, treatment, comorbidity and education | Danish Cancer Society | 50.000 |
| Grønberg, Bjørn H. | A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer | Norwegian University of Science and Technology and St. Olavs hospital, Trondheim University Hospital | 40.000 |
| Gunnarsson, Ulf | MSI in sporadic colorectal cancer: register data regarding cancer in other organs, clinical presentation and immune response | Umeå University, Department of Surgical and Perioperative Sciences | 40.000 |
| Harris, Jennifer | Genetic Epidemiology and Familial Risk of Cross-Cancer Associations: A Nordic Twin Study-II | The Norwegian Institute of Public Health | 40.000 |
| Hellström Lindberg, Eva | Nordic Collaborative Clinical Database Initiative and Allogeneic Stem Cell Transplantation Project for Myelodysplastic Syndromes | Department of Medicine, Karolinska Institutet, Karolinska University Hospital | 40.000 |
| Jakola, Asgeir S. | Disulfiram response as add-on to chemotherapy in recurrent glioblastoma | Sahlgrenska University Hospital and St.Olavs Hospital | 40.000 |
| Johansen, Christoffer | Late effects in Nordic cancer patients - LECA | Rigshospitalet and the Danish Cancer Society Research Center | 50.000 |
| Jonsson, Håkan | Estimation of Overdiagnosis in Breast Cancer Screening | Umeå University | 40.000 |
| Kristinsson, Sigurdur Yngvi | Comorbidity and multiple myeloma | University of Iceland | 30.000 |
| Lagergren, Jesper | Antireflux surgery and cancer risk in the Nordic Antireflux Surgery Cohort (NordASCo) | Karolinska Institutet | 40.000 |
| Lindman, Henrik | Nordic TRIP – a randomized phase-3 trial of adjuvant and neoadjuvant treatment in early triple negative breast cancer | Onkologiska Kliniken, Akademiska Sjukhuset, Uppsala | 30.000 |
| Murtola, Teemu | Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial | University of Tampere, Faculty of Medicine and Life Sciences | 40.000 |
| Pettersson, Kim | Nanoparticle aided glycovariant biomarkers for the early detection of epithelial ovarian cancer | Department of Biochemistry, Division of Biotechnology, University of Turku | 30.000 |
| Pukkala, Eero | New wave of joint Nordic studies on work and cancer | Finnish Cancer Registry / University of Tampere | 40.000 |

| | | | |
|-------------------------------------|---|--|----------------|
| Rodriguez-Wallberg, Kenny Alexandra | An investigation of GnRHa exposure in connection with cancer treatment: Effects on fecundity, cancer recurrence and death | Karolinska Institutet and Karolinska University Hospital | 40.000 |
| Tryggvadóttir, Laufey | Prognostic Factors, Treatment and Breast Cancer Survival in Nordic BRCA2 Mutation Carriers | University of Iceland, Icelandic Cancer Society | 40.000 |
| Total | | | 750.000 |

NCU Strategic Funds

The Nordic Cancer Union provides funding for projects of high standard within the field of cancer amounting to 250.000 euros annually. The projects funded by the NCU meet strict requirements, with priority given to projects and initiatives that reflect the current general strategy of the NCU and have added Nordic value.

New regulation and guidelines were adopted by the board of the Nordic Cancer Union in 2016, and came into use immediately.

Researchers working in two or more Nordic countries must be involved in the project. The projects applied for must have cancer relevance, be uniquely suited to be carried out within the Nordic countries, and the effect of collaboration should be synergistic.

The projects funded in 2017 were Nordcan, Nordic Summer School in Cancer Epidemiology and Nordic NECT, as can be seen from the following table.

Confirmed financial support 2017

| | |
|---|---------------|
| Secretariat for Nordic NECT | 50.000 euros |
| NORDCAN | 35.500 euros |
| Nordic Summer School in Cancer Epidemiology | 46.150 euros |
| Total confirmed support | 131.650 euros |

Confirmed strategic project overview regarding 2015-2019 - *see tabel 3 on page 17.*

Table 3: Confirmed strategic project overview regarding 2015-2019

Strategic projects overview

Project overview - Agreed by the Board of NCU, in Feb. 2018, All amounts in EURO

| | | Total support | Planned in 2015 | Planned in 2016 | Planned in 2017 | Planned in 2018 | Planned in 2019 |
|--|--------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Confirmed financial support | | | | | | | |
| Secretariat for Nordic NECT | 1 | 148.000 | 48.000 | 50.000 | 50.000 | | |
| UICC/IARC summer school | 2 | 49.200 | 16.400 | 16.400 | 16.400 | | |
| UICC/IARC summer school, revised | 2a | -16.400 | | | -16.400 | | |
| NORDCAN | 3 | 106.500 | | 35.500 | 35.500 | 35.500 | |
| Nordic Summer School in Cancer Epidemiology .. | 4 | 92.300 | | | 46.150 | 46.150 | |
| Total confirmed support | | 379.600 | 64.400 | 101.900 | 131.650 | 81.650 | 0 |
| Actual payments | | | | | | | |
| Secretariat for Nordic NECT | 1 | 148.000 | | | 98.000 | | |
| UICC/IARC summer school | 2 & 2a | 32.800 | 13.227 | 14.137 | -3.677 | | |
| NORDCAN | 3 | 106.500 | | | 71.000 | | |
| Nordic Summer School in Cancer Epidemiology .. | 4 | 92.300 | | | 92.300 | | |
| Total actual payments | | 379.600 | 13.227 | 14.137 | 257.623 | 0 | 0 |

Notes:

1. Confirmed on a Board Meeting in Helsingör in September 2015
2. Confirmed on a Board Meeting in Reykjavik 22 May 2015
- 2a Revised support for 2016, on a Board Meeting in Stockholm 17 February 2017
3. Confirmed on a Board Meeting in Oslo 19 February 2016
4. Confirmed on a Board Meeting in Copenhagen 25 November 2016

| | | Total support | Planned in 2015 | Planned in 2016 | Planned in 2017 | Planned in 2018 | Planned in 2019 |
|--|--------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Unpaid confirmed financial support | | | | | | | |
| Secretariat for Nordic NECT | 1 | 148.000 | | | 50.000 | | |
| UICC/IARC summer school | 2 & 2a | 32.800 | | | | | |
| NORDCAN | 3 | 106.500 | | | | 35.500 | |
| Nordic Summer School in Cancer Epidemiology .. | 4 | 92.300 | | | | | |
| Total confirmed support | | 379.600 | 0 | 0 | 50.000 | 35.500 | 0 |

NCU financial statements 2017

The NCU financial statements 2017 is attached as Appendix 1.

NCU member information



Kræftens Bekæmpelse

The Danish Cancer Society

Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark

Managing Director: Leif Vestergaard Pedersen

Phone: +45 35 25 75 00 Email: info@cancer.dk

www.cancer.dk

krabbameinsfelagið



The Faroese Cancer Society

Grønlandsvegur 58, Boks 1216, FO-110, Tórshavn

Director: Jansy Gaardlykke

Phone: +298 31 79 59 Email: ffk@krabbamein.fo

www.krabbamein.fo



Cancer Society of Finland

The Cancer Society of Finland

Unioninkatu 22, 00-130 Helsinki, P.B. 238, FIN-00131 Helsinki

Secretary General: Sakari Karjalainen, MD, PH.D.

Phone: +358 9 135 331 Email: society@cancer.fi

www.cancer.fi



The Icelandic Cancer Society

Skógarhlíð 8, IS-105 Reykjavík, Iceland

Director: Guðfinna Halla Thorvaldsdóttir

Phone: +354 540 1900 Email: krabb@krabb.is

www.krabb.is



The Norwegian Cancer Society

Visiting address: Kongens gate 6, 0153 Oslo, Postal address: PO Box 4 Sentrum, 0101 Oslo, Norway

Secretary General: Anne Lise Ryel

Phone +47 815 70 477 Email: servicetorget@kreftforeningen.no

www.kreftforeningen.no



The Swedish Cancer Society

Visiting address: David Bagares gata 5, Postal address: 101 55 Stockholm, Sweden

Secretary General: Ulrika Årehed Kågström

Phone: +46 8 677 10 00 Email: info@cancerfonden.se

www.cancerfonden.se



Nordic Cancer Union

Financial Statements 2017

Approved by the NCU Board 19. feb. 2018

Nordic Cancer Union
Skógarhlíð 8
105 Reykjavík

Iceland

Contents

| | |
|---|---|
| Report on Review of Financial Statements | 1 |
| Endorsement and Statement by the Board | 2 |
| Income statement | 3 |
| Balance sheet | 4 |
| Accounting Policies and Explanatory Notes | 5 |

Report on Review of Financial Statements

To the Board of Nordic Cancer Union

We have reviewed the accompanying financial statements of Nordic Cancer Union that comprise the endorsement and statement by the board of directors, statement of financial position as at December 31, 2017, the income statement and a summary of significant accounting policies and other explanatory information.

Board's responsibility

The Board is responsible for the preparation and fair presentation of these financial statements in accordance with general accepted accounting practice and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' responsibility

Our responsibility is to express a conclusion on the accompanying financial statements. We conducted our review in accordance with International Standard on Review Engagements (ISRE) 2400, Engagements to Review Historical Financial Statements. ISRE 2400 requires us to conclude whether anything has come to our attention that causes us to believe that the financial statements, taken as a whole, are not prepared in all material respects in accordance with the applicable financial reporting framework. This Standard also requires us to comply with relevant ethical requirements.

A review of financial statements in accordance with ISRE 2400 is a limited assurance engagement. The practitioner performs procedures, primarily consisting of making inquiries of management and others within the entity, as appropriate, and applying analytical procedures, and evaluates the evidence obtained.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing. Accordingly, we do not express an audit opinion on these financial statements.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of Nordic Cancer Union as at December 31, 2017 and its financial performance for the year then ended, in accordance with the general accepted accounting practice.

Reykjavík, 16 January 2018

Ernst & Young ehf.



Rögnvaldur Dofri Pétursson
State Authorized Public Accountant

Endorsement and Statement by the Board

The Financial Statements for Nordic Cancer Union are prepared in accordance with general accepted accounting practice.

The board consider the accounting policies used to be appropriate, such that the Financial Statements gives a true and fair view of the Income Statement for the year 2017 and the Balance Sheet at 31 December 2017.

We hereby submit the Financial Statement for the year 2017 to the Board of Nordic Cancer Union for approval.

Reykjavík, 16 January 2018



Ragnheiður Haraldsdóttir

Chairman

Income statement 2017

All amounts in EURO

| | Notes | Actual 2017 | Budget 2017 | Actual 2016 |
|-----------------------------------|-------|-----------------|------------------|------------------|
| Income | | | | |
| Income from NCU members | | 918.810 | 918.810 | 1.077.863 |
| Interest from bank accounts | | 0 | 0 | 306 |
| Nordic Summer School repaid | | 3.677 | 0 | 2.263 |
| | | <u>922.487</u> | <u>918.810</u> | <u>1.080.432</u> |
| Activity | | | | |
| Research | | 750.000 | 750.000 | 750.000 |
| Strategic projects | 4 | 131.650 | 250.000 | 101.900 |
| | | <u>881.650</u> | <u>1.000.000</u> | <u>851.900</u> |
| Result before other cost | | 40.837 | (81.190) | 228.532 |
| Other cost | | | | |
| Secretariat function | 5 | 65.000 | 65.000 | 65.000 |
| Travel cost | 6 | 7.217 | 15.000 | 10.782 |
| Other cost | 7 | 8.395 | 12.000 | 5.697 |
| | | <u>80.612</u> | <u>92.000</u> | <u>81.479</u> |
| Result for the year | | <u>(39.775)</u> | <u>(173.190)</u> | <u>147.053</u> |

Balance Sheet 31 December 2017

All amounts in EURO

Assets

| | Notes | 2017 | 2016 |
|---------------------------------|-------|----------------|------------------|
| Current Assets | | | |
| Short-term receivables | 8 | 46.150 | 301.802 |
| Cash and cash equivalents | | <u>198.059</u> | <u>853.580</u> |
| Total Current Assets | | <u>244.209</u> | <u>1.155.382</u> |

| | | |
|---------------------|----------------|------------------|
| Total Assets | <u>244.209</u> | <u>1.155.382</u> |
|---------------------|----------------|------------------|

Equity and Liabilities

Equity

| | | | |
|--------------------------------|---|-----------------|----------------|
| Equity at year beginning | 3 | 226.190 | 79.137 |
| Result from operation | 3 | <u>(39.775)</u> | <u>147.053</u> |
| Total equity | | <u>186.415</u> | <u>226.190</u> |

Liabilities

Current Liabilities

| | | | |
|----------------------------------|---|---------------|----------------|
| Research | | 0 | 750.000 |
| Other current liabilities | 9 | <u>57.794</u> | <u>179.192</u> |
| Total Current Liabilities | | <u>57.794</u> | <u>929.192</u> |

| | | |
|--------------------------|---------------|----------------|
| Total Liabilities | <u>57.794</u> | <u>929.192</u> |
|--------------------------|---------------|----------------|

| | | |
|-------------------------------------|----------------|------------------|
| Total Equity and Liabilities | <u>244.209</u> | <u>1.155.382</u> |
|-------------------------------------|----------------|------------------|

Notes to the Financial Statements 2017

All amounts in EURO

1. General information

The Nordic Cancer Union is a collaborative body for cancer societies in the Nordic countries. The registered office is now at Skógarhlíð 8, 104 Reykjavík, Iceland.

2. Summary of accounting policies

Basis of preparation and statement of compliance

The Financial Statements are prepared in accordance with general accepted accounting practice. The Financial Statements have been prepared on a going concern basis and under the historical cost convention. The Financial Statements are presented in EURO, except when otherwise indicated.

Use of estimates and judgements

The preparation of the Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. Use of available information and application of judgement are inherent in the formation of estimates. Actual results in the future could differ from such estimates and the differences may be material to the Interim Financial Statements.

Foreign currency translation

Foreign currency transactions

Transactions in foreign currencies are initially recorded at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the exchange rate ruling at the balance sheet date. Gains and losses resulting from the translation of foreign currency transactions are taken to the income statement.

Accounts receivables

Accounts receivables are initially recognised at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the association will not be able to collect all amounts due according to the original terms of the receivables. The directors assessment is that no provision is needed at year end.

Cash and cash equivalents

Cash and cash equivalents includes cash on hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts, if any are shown within borrowings in current liabilities on the balance sheet.

Notes to the Financial Statements 2017

All amounts in EURO

Trade payables and other payables

Trade payables and other payables are recognised initially at the transaction price or fair value. These financial liabilities are normally non-interest bearing. Trade payables are normally settled within 2 months, and other payables within 12 months.

Income

Income from NCU members is contribution from NCU members.

Interest income on bank accounts is recognised when earned.

3. Equity

Changes in equity are specified as follows:

| | Retained earnings | Total |
|-----------------------|----------------------|----------------|
| Equity at 1/1 | 226.190 | 226.190 |
| Profit (loss) | (39.775) | (39.775) |
| Equity at 31/12 | <u>186.415</u> | <u>186.415</u> |

Specifications

| <i>All amounts in EURO</i> | | |
|---|----------------|----------------|
| | Actual 2017 | Actual 2016 |
| Income from NCU members | | |
| Members fee | 918.810 | 1.077.863 |
| | 918.810 | 1.077.863 |
| Nordic Summer School repaid | | |
| Nordic Summer School repaid | 3.677 | 2.263 |
| | 3.677 | 2.263 |
| 4. Strategic projects | | |
| Secretariat for Nordic Network NECT | 50.000 | 50.000 |
| UICC/IARC summer School | 16.400 | 16.400 |
| UICC/IARC summer School, revised 2015 | (16.400) | 0 |
| NORDCAN | 35.500 | 35.500 |
| Nordic Summer School in Cancer-Epidemiology | 46.150 | 0 |
| | 131.650 | 101.900 |
| Research | | |
| Grants | 750.000 | 750.000 |
| | 750.000 | 750.000 |
| 5. Secretariat function | | |
| Professional service | 21.989 | 22.655 |
| Commission Norge | 32.500 | 32.500 |
| Other office and administration cost | 10.511 | 9.845 |
| | 65.000 | 65.000 |
| 6. Travel cost | | |
| Travel cost Iceland | 3.821 | 4.990 |
| Travel cost Faroe Island | 3.396 | 5.792 |
| | 7.217 | 10.782 |
| 7. Other cost | | |
| IT-expenses | 883 | 855 |
| Travel expenses | 2.947 | 0 |
| Conference fee and related cost | 3.888 | 4.648 |
| Other office and administration cost | 677 | 194 |
| | 8.395 | 5.697 |
| 8. Short-term receivables | | |
| Prepaid financial support | 46.150 | 0 |
| Members fee | 0 | 301.802 |
| | 46.150 | 301.802 |

Specifications

All amounts in EURO

| | Actual 2017 | Actual 2016 |
|--|----------------|----------------|
| 9. Other current liabilities | | |
| Secratarial for Nordic NECT | 50.000 | 98.000 |
| NORDCAN | 0 | 35.500 |
| UICC/IARC summer school | 0 | 16.400 |
| Krabbameinsfélag Íslands | 4.088 | 19.573 |
| Krabbameinsfelagid Faroe Islands | 3.396 | 5.836 |
| IE radgjöf og greining | 0 | 3.883 |
| Ernst & Young ehf. | 310 | 0 |
| | <u>57.794</u> | <u>179.192</u> |